This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).
Horizon Pharma Gets Health Canada Approval for Procysbi
by Zacks Equity Research
Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio
by Arpita Dutt
The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.
Sanofi: Should Value Investors Consider SNY Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.
Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug
by Zacks Equity Research
Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.
Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
by Zacks Equity Research
Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.
Intercept (ICPT) Releases Data from Phase II Flint Trial
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.
Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has signed a deal to sell iNova Pharmaceuticals for $930 million in cash to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group.
3 Large Cap Pharma Stocks to Buy Now
by Ryan McQueeney
Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!
Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.
Is the Options Market Predicting a Spike in Sanofi (SNY) Stock?
by Zacks Equity Research
Investors in Sanofi (SNY) need to pay close attention to the stock based on moves in the options market lately.
Amgen Files for Repatha in the U.S., EU for Expanded Use
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.
Sanofi (SNY): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
One stock that might be an intriguing choice for investors right now is Sanofi (SNY).
Regeneron Announces Positive Data on Carcinoma Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Big Pharma Diabetes Drugs Not So Sweet. What's in Store?
by Zacks Equity Research
Aales of diabetes drugs from most large pharma companies slipped in the first quarter.
5 Drug Stocks in Focus on World MS Day
by Arpita Dutt
Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.
Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?
by Zacks Equity Research
We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.
Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals
by Zacks Equity Research
After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data
by Arpita Dutt
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline
by Zacks Equity Research
We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.
Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
by Zacks Equity Research
Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).
Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?
by Arpita Dutt
Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More
by Arpita Dutt
This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.